MEI Pharma Files 8-K for Disclosure and Exhibits

Ticker: LITS · Form: 8-K · Filed: May 21, 2024 · CIK: 1262104

Mei Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyMei Pharma, INC. (LITS)
Form Type8-K
Filed DateMay 21, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00000002
Sentimentneutral

Sentiment: neutral

Topics: disclosure, filing

TL;DR

MEI Pharma filed an 8-K, standard procedure, no major news.

AI Summary

MEI Pharma, Inc. filed an 8-K on May 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the reporting of these items.

Why It Matters

This filing indicates MEI Pharma is providing necessary disclosures and financial information to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not report any new material events, financial results, or significant corporate actions.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by MEI Pharma, Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on May 21, 2024.

In which state is MEI Pharma, Inc. incorporated?

MEI Pharma, Inc. is incorporated in Delaware.

What is the principal executive office address for MEI Pharma, Inc.?

The principal executive office address is 11455 El Camino Real, Suite 250, San Diego, California, 92130.

Does this filing report any specific new material events or financial results?

No, this filing primarily serves as a notification of Regulation FD Disclosure and the submission of Financial Statements and Exhibits, without detailing specific new material events or financial results within the provided text.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-21 13:00:22

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 21, 2024, Richard Ghalie, M.D., the Chief Medical Officer of MEI Pharma, Inc., will participate in a panel at the Brookline Virtual MDS and AML Symposium. During the panel discussion Dr. Ghalie will discuss clinical data from the ongoing clinical evaluation of voruciclib in patients with Acute Myeloid Leukemia, which are included in the presentation attached as Exhibit 99.1 to this Form 8-K and are incorporated by reference into this Item 7.01. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 MEI Pharma, Inc., Corporate Presentation May 21, 2024 104 Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI Phama, Inc. Date: May 21, 2024 By: /s/ David M. Urso David M. Urso Chief Executive Officer and Director

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing